GNPX
Genprex, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.50
+2.19%Aug 18, 2026, 11:00 UTC
Genprex entered into a development and manufacturing agreement with a leading U.S.-based CDMO to scale up manufacturing of its diabetes gene therapy program, transitioning from research-grade to clinical and commercial-ready production.
Source:Aug 3, 2026, 11:00 UTC
Genprex announced a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer clinical trials.
Source: